{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:12:31Z","timestamp":1793034751467,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"DH | National Institute for Health Research","doi-asserted-by":"publisher","award":["PR-PRU-1217-21601"],"award-info":[{"award-number":["PR-PRU-1217-21601"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"DH | National Institute for Health Research","doi-asserted-by":"publisher","award":["PR-PRU-1217-21601"],"award-info":[{"award-number":["PR-PRU-1217-21601"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2022,5,18]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Population breast screening services in England were suspended in March 2020 due to the COVID-19 pandemic. Here, we estimate the number of breast cancers whose detection may be delayed because of the suspension, and the potential impact on cancer deaths over 10 years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We estimated the number and length of screening delays from observed NHS Breast Screening System data. We then estimated additional breast cancer deaths from three routes: asymptomatic tumours progressing to symptomatically diagnosed disease, invasive tumours which remain screen-detected but at a later date, and ductal carcinoma in situ (DCIS) progressing to invasive disease by detection. We took progression rates, prognostic characteristics, and survival rates from published sources.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We estimated that 1,489,237 women had screening delayed by around 2\u20137 months between July 2020 and June 2021, leaving 745,277 outstanding screens. Depending on how quickly this backlog is cleared, around 2500\u20134100 cancers would shift from screen-detected to symptomatic cancers, resulting in 148\u2013452 additional breast cancer deaths. There would be an additional 164\u2013222 screen-detected tumour deaths, and 71\u201397 deaths from DCIS that progresses to invasive cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>An estimated 148\u2013687 additional breast cancer deaths may occur as a result of the pandemic-related disruptions. The impact depends on how quickly screening services catch up with delays.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-022-01714-9","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T12:02:58Z","timestamp":1643803378000},"page":"1355-1361","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["The projected impact of the COVID-19 lockdown on breast cancer deaths in England due to the cessation of population screening: a national estimation"],"prefix":"10.1038","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4901-7922","authenticated-orcid":false,"given":"Stephen W.","family":"Duffy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Seedat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olive","family":"Kearins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Press","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Walton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Myles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Vulkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Mackie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"key":"1714_CR1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/20502877.2021.1917101","volume":"27","author":"DG Smithard","year":"2021","unstructured":"Smithard DG, Haslam J. COVID-19 pandemic healthcare resource allocation, age and frailty. New Bioeth. 2021;27:127\u201332.","journal-title":"New Bioeth"},{"key":"1714_CR2","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/S2213-2600(20)30580-4","volume":"9","author":"A Supady","year":"2021","unstructured":"Supady A, Curtis JR, Abrams D, Lorusso R, Bein T, Boldt J, et al. Allocating scarce intensive care resources during the COVID-19 pandemic: practical challenges to theoretical frameworks. Lancet Respir Med. 2021;9:430\u20134.","journal-title":"Lancet Respir Med"},{"key":"1714_CR3","doi-asserted-by":"crossref","unstructured":"The benefits and harms of breast cancer screening: an independent review. The Lancet. 2012;380:1778-86.","DOI":"10.1016\/S0140-6736(12)61611-0"},{"key":"1714_CR4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.7326\/M19-2125","volume":"172","author":"HJ Sch\u00fcnemann","year":"2020","unstructured":"Sch\u00fcnemann HJ, Lerda D, Quinn C, Follmann M, Alonso-Coello P, Rossi PG, et al. Breast cancer screening and diagnosis: a synopsis of the european breast guidelines. Ann Intern Med. 2020;172:46\u201356.","journal-title":"Ann Intern Med"},{"key":"1714_CR5","unstructured":"Screening and Immunisations Team, NHS Digital. Breast Screening Programme: England 2018-19. Leeds: NHS Digital; 2020."},{"key":"1714_CR6","doi-asserted-by":"crossref","unstructured":"Maringe C, Spicer J, Morris M, Purushotham A, Nolte E, Sullivan R, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 2020;21:1023-34.","DOI":"10.1016\/S1470-2045(20)30388-0"},{"key":"1714_CR7","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1016\/j.ejca.2007.01.016","volume":"43","author":"RW Blamey","year":"2007","unstructured":"Blamey RW, Ellis IO, Pinder SE, Lee AH, Macmillan RD, Morgan DA, et al. Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990\u20131999. Eur J Cancer (Oxf, Engl: 1990). 2007;43:1548\u201355.","journal-title":"Eur J Cancer (Oxf, Engl: 1990)"},{"key":"1714_CR8","unstructured":"NHS Breast Screening Programme and Association of Breast Surgery Screening Audit Group. An audit of screen detected breast cancers for the year of screening April 2018 to March 2019 England Public Health England, Association of Breast Surgery; 2020."},{"key":"1714_CR9","unstructured":"Public Health England. National Cancer Registration and Analysis Service (NCRAS) England: Public Health England; 2020; https:\/\/www.gov.uk\/guidance\/national-cancer-registration-and-analysis-service-ncras."},{"key":"1714_CR10","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/bjc.2012.596","volume":"108","author":"S Taghipour","year":"2013","unstructured":"Taghipour S, Banjevic D, Miller AB, Montgomery N, Jardine AK, Harvey BJ. Parameter estimates for invasive breast cancer progression in the Canadian National Breast Screening Study. Br J Cancer. 2013;108:542\u20138.","journal-title":"Br J Cancer"},{"key":"1714_CR11","unstructured":"Cancer Research UK. Breast cancer survival statistics. https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/breast-cancer\/survival. Last accessed 1st June 2021."},{"key":"1714_CR12","first-page":"9","volume":"2","author":"H Chen","year":"1997","unstructured":"Chen H, Duffy S, Tabar L, Day N. Markov chain models for progression of breast cancer. Part I: tumour attributes and the preclinical screen-detectable phase. J Epidemiol Biostat. 1997;2:9\u201323.","journal-title":"J Epidemiol Biostat."},{"key":"1714_CR13","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/annonc\/mdp301","volume":"21","author":"G Wishart","year":"2010","unstructured":"Wishart G, Greenberg D, Chou P, Brown C, Duffy S, Purushotham A. Treatment and survival in breast cancer in the Eastern Region of England. J Ann Oncol. 2010;21:291\u20136.","journal-title":"J Ann Oncol"},{"key":"1714_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01287-6","volume":"22","author":"S Chootipongchaivat","year":"2020","unstructured":"Chootipongchaivat S, van Ravesteyn NT, Li X, Huang H, Weedon-Fekj\u00e6r H, Ryser MD, et al. Modeling the natural history of ductal carcinoma in situ based on population data. Breast Cancer Res. 2020;22:53.","journal-title":"Breast Cancer Res"},{"key":"1714_CR15","unstructured":"Cancer Research UK. A trial to evaluate an age extension to the NHS Breast Screening Programme 2020; https:\/\/www.cancerresearchuk.org\/about-cancer\/find-a-clinical-trial\/a-study-to-evaluate-an-age-extension-of-the-nhs-breast-screening-programme."},{"key":"1714_CR16","unstructured":"Department of Health and Social Care, Office for National Statistics, Government Actuary\u2019s Department, Home Office. Direct and Indirect Impacts of COVID-19 on Excess Deaths and Morbidity. 2020."},{"key":"1714_CR17","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1038\/bjc.2013.177","volume":"108","author":"MG Marmot","year":"2013","unstructured":"Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. Br J cancer. 2013;108:2205\u201340.","journal-title":"Br J cancer"},{"key":"1714_CR18","unstructured":"Richards M. The independent review of adult screening programmes in England. England: NHS; 2019."},{"key":"1714_CR19","doi-asserted-by":"crossref","unstructured":"Breast Screening Working Group (WG2) of the Covid-19 and Cancer Global Modelling Consortium. The impact of the Covid-19 pandemic on breast cancer early detection and screening. Prev Med. 151:106585.","DOI":"10.1016\/j.ypmed.2021.106585"},{"key":"1714_CR20","doi-asserted-by":"crossref","unstructured":"Kregting LM, Kaljouw S, de Jonge L, Jansen EEL, Peterse EFP, Heijnsdijk EAM, et al. Effects of cancer screening restart strategies after COVID-19 disruption. Br J Cancer. 2021;124:1516\u201323.","DOI":"10.1038\/s41416-021-01261-9"},{"key":"1714_CR21","doi-asserted-by":"crossref","unstructured":"Yong JH, Mainprize JG, Yaffe MJ, Ruan Y, Poirier AE, Coldman A, et al. The impact of episodic screening interruption: COVID-19 and population-based cancer screening in Canada. J Med Screen. 2020:28:100-107.","DOI":"10.1177\/0969141320974711"},{"key":"1714_CR22","unstructured":"Nickson C, Procopio P, Deij S, Velentzis L. COVID-19 scenario modelling for cancer screening programs, the BreastScreen Australia Program. In: Division CR, editor. New South Wales: Cancer Council NSW; 2020."},{"key":"1714_CR23","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/S1470-2045(20)30392-2","volume":"21","author":"A Sud","year":"2020","unstructured":"Sud A, Torr B, Jones ME, Broggio J, Scott S, Loveday C, et al. Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study. Lancet Oncol. 2020;21:1035\u201344.","journal-title":"Lancet Oncol"},{"key":"1714_CR24","doi-asserted-by":"publisher","first-page":"e043828","DOI":"10.1136\/bmjopen-2020-043828","volume":"10","author":"AG Lai","year":"2020","unstructured":"Lai AG, Pasea L, Banerjee A, Hall G, Denaxas S, Chang WH, et al. Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study. BMJ Open. 2020;10:e043828.","journal-title":"BMJ Open"},{"key":"1714_CR25","doi-asserted-by":"crossref","unstructured":"Hanna TP, King WD, Thibodeau S, Jalink M, Paulin GA, Harvey-Jones E, et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ. 2020;371:m4087.","DOI":"10.1136\/bmj.m4087"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01714-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01714-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01714-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T23:05:10Z","timestamp":1651014310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01714-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,5,18]]}},"alternative-id":["1714"],"URL":"https:\/\/doi.org\/10.1038\/s41416-022-01714-9","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,2]]},"assertion":[{"value":"14 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval and consent to participate were not required for this study as no primary data were collected.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"FS and AM are employed by the UK National Screening Committee (UK NSC), hosted at the Office for Health Improvement and Disparities within the Department of Health and Social Care. MP, JW and OK were employed by Public Health England during this project and are now employed by NHS England and NHS Improvement. All other authors declare no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}